Opko Health, Inc. (OPK) insider have most recently took part in a trading activity. On Jun 28, 2017 Frost Phillip Md Et Al, CEO & Chairman, 10% Owner bought 1,800 shares having total worth of $12,366 at the price of $6.87 per share, following the transaction a total of 186,709,556 shares owned by Frost Phillip Md Et Al. Before this latest buy, Frost Phillip Md Et Al purchased OPK at 147 other times during the past twelve months, for a total investment of $272.98M at an average of $8.62 per share.
The stock has experienced a total of 50 insider trades in the past three months. These trades include 50 buy trades. Furthermore, over the past 12 months , the stock was traded 156 times by insiders. In 1 of these trades, the insider was a seller while an employee of the company was the buyer in 155 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of Opko Health, Inc. (OPK) traded up 2.39% on Jun 28, 2017, hitting $6.86. 2,921,283 shares of the company’s stock traded hands. Opko Health, Inc. has a 52 week low of $6.14 and a 52 week high of $11.91. The company’s market cap is $6,160 million.
Opko Health, Inc. (OPK) last announced its earnings results on May 9, 2017. The company reported -0.06 earnings per share (EPS) for the quarter, lower than the consensus estimate of -0.04 by $0.02. The company had revenue of $296 million for the quarter, compared to the consensus estimate of $313 million. During the same quarter in the previous year, the company posted -0.02 earnings per share. The company’s revenue for the quarter was up 2% on a year-over-year basis.
|earnings per share||-0.06||-0.04||0.02||-0.02||0.00||-0.10||-0.04||-0.26||-0.12||-0.01|
Opko Health, Inc. was originally incorporated in Delaware in October 1991 under the name Cytoclonal Pharmaceutics, Inc., which was later changed to eXegenics, Inc. On June 8, 2007, the Company changed its name to OPKO Health, Inc. It is a biopharmaceutical and diagnostics company, which is focused on the discovery, development, and commercialization of proprietary pharmaceuticals, diagnostic and imaging systems and instrumentation products for the treatment, diagnosis and management of ophthalmic diseases and conditions. The Company’s business presently consists of the development of ophthalmic pharmaceuticals and the development, commercialization and sale of ophthalmic diagnostic and imaging systems and instrumentation products. The Company operates a U.S.-based laboratory certified under the Clinical Laboratory Improvement Amendments of 1988, as amended (“CLIA”), with a urologic focus that it expects will serve as a commercial platform for the U.S. launch of OPKO’s next generation test for the early detection of prostate cancer. In addition, it operates a specialty active pharmaceutical ingredients (“APIs”) manufacturer in Israel, which it expects will play a valuable role in the development of its pipeline of molecules and compounds for their proprietary molecular diagnostic and therapeutic products. It continues to actively explore opportunities to acquire complementary pharmaceuticals, compounds, technologies, and businesses. In late 2011, it acquired a novel diagnostic instrument system that provides rapid, high performance blood test results and enables complex tests to be run in point-of-care settings. The Company faces competition from competitors for its instrumentation products located in the United States and abroad, which competitors include companies with a far more diverse product offering and greater market presence than its, such as Carl Zeiss Meditec, Topcon Corporation, and Heidelberg Engineering, as well as a number of smaller competitors and smaller start-up companies that might also have competing technologies and products. The Company is also subject to various federal, state, and international laws pertaining to health care ‘fraud and abuse,’ including anti-kickback laws and false claims laws.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018